68Ga-DOTA-TATE PET/CT 对转移性脊索瘤生长抑素受体表达的分子成像:与18F-FDG 的比较
本文报告一例53岁男性转移性脊索瘤患者,为再分期及评估靶向放射性核素治疗潜力,接受了18F-FDG 与68Ga-DOTA-TATE PET/CT 检查;两种显像均见脊索瘤转移灶示踪剂摄取增高。作者指出,除葡萄糖代谢增高外,本病例还凸显了68Ga-DOTA-TATE PET/CT 用于脊索瘤再分期及靶向放射性核素治疗选择的潜力。
要点
- 53岁男性转移性脊索瘤患者接受18F-FDG 与68Ga-DOTA-TATE PET/CT 再分期。
- 两种 PET 显像均见脊索瘤转移灶示踪剂摄取增高。
- 作者认为68Ga-DOTA-TATE PET/CT 在脊索瘤再分期与靶向放射性核素治疗方面有潜力。
核心结论
- 作者认为,本病例除显示脊索瘤葡萄糖代谢增高外,还凸显了68Ga-DOTA-TATE PET/CT 用于脊索瘤再分期以及该病变靶向放射性核素治疗的潜力。
研究设计与样本
- 个案报告:1例53岁男性转移性脊索瘤患者,为疾病再分期及评估靶向放射性核素治疗潜力,接受18F-FDG 与68Ga-DOTA-TATE PET/CT 检查。
主要发现
- 18F-FDG 与68Ga-DOTA-TATE PET 显像均显示脊索瘤转移灶示踪剂摄取增高。
- 作者指出脊索瘤存在葡萄糖代谢增高,并强调68Ga-DOTA-TATE PET/CT 在再分期及靶向放射性核素治疗方面的潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chordoma is a rare slow-growing neoplasm of neuroectodermal origin, which frequently recurs after removal and has the potential to metastasize. We present the case of a 53-year-old man with metastasizing chordoma who underwent F-FDG and Ga-DOTA-TATE PET/CT for restaging of disease and for evaluation of targeted radionuclide therapy potential. On both F-FDG and Ga-DOTA-TATE PET scans, increased tracer accumulation was observed in chordoma metastases. Besides the increased glucose metabolism in chordoma, this case highlights the potential of Ga-DOTA-TATE PET/CT for restaging of chordoma as well the option of targeted radionuclide therapy in this entity.
引用
- Derlin T, Sohns JM, Hueper K, et al. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG. Clin Nucl Med. 2017. PMID: 28166150. doi:10.1097/RLU.0000000000001576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。